White Papers

Home ▸ White Papers

Choose from a variety of resources to get a better understanding of Syngene’s point of view, expertise or approach to drug discovery, development and manufacturing to ensure client success.

Resource Types

Inside the growing precision therapy market and the crucial role of pDNA manufacturing

Challenges in pDNA manufacturing for precision therapies, and how CDMOs, who cater to the requirements of multiple companies and develop platform processes to achieve the much-needed economy of scale, are being seen as a possible solution.

Read

Harnessing artificial intelligence and digital technologies across the biopharma value chain

Key considerations when using AI, and how Syngene applies AI and digital technologies to accelerate drug discovery, development, and manufacturing for its clients.

Read

ADCs as biological missiles for targeted therapies

Explore the market growth of ADCs, innovations in the ADC space, and the future of ADCs as a targeted therapy for various diseases, including cancer.

Read

Antibody Drug Conjugates: Re-emergence of an old modality for targeted therapies

Explore the key challenges in ADC development and how Syngene, a leading CRO/CDMO, is supporting clients in the discovery, development, and manufacturing of innovative ADC molecules.

Read

How to overcome solubility challenges by applying amorphous solid dispersion: An end-to-end solution

Discover the successful approach to preparing, screening, characterizing, and dosing amorphous solid dispersions (ASDs) in preclinical and early clinical development.

Read

Cracking the Code: Transformative role of pDNA in advanced modalities

Reasons behind the rise in demand for pDNA and what to look for in a pDNA engineering and manufacturing partner when deciding to outsource.

Read

Pharma Supply Chain: From Fragile to Agile

CDMOs bolster supply networks with additional capabilities to make themselves resilient to potential challenges and ensure secure supplies to customers.

Read

Quality management paradigm shift: Risk-centric practices come center stage

CDMOs have moved to risk-based quality management systems comprising highly integrated and digitalized processes powered by data to ensure drug quality.

Read

Protein therapeutics to amp up outsourcing in animal health

With the boom in pet ownership and rising awareness about pet health, veterinary drug makers are betting big on protein therapeutics and outsourcing biologics development to CDMOs.

Read